logo
Get ready for several years of killer heat, top weather forecasters warn

Get ready for several years of killer heat, top weather forecasters warn

CTV News5 days ago

Ricky Leath, an outreach specialist with the City of Miami, talks with Bei Zhao, right, as he works with the Miami-Dade County Homeless Trust to distribute bottles of water and other supplies to the homeless population, helping them manage high temperatures, May 15, 2024, in Miami. (AP Photo/Lynne Sladky, File)
WASHINGTON — Get ready for several years of even more record-breaking heat that pushes Earth to more deadly, fiery and uncomfortable extremes, two of the world's top weather agencies forecast.
There's an 80% chance the world will break another annual temperature record in the next five years, and it's even more probable that the world will again exceed the international temperature threshold set 10 years ago, according to a five-year forecast released Wednesday by the World Meteorological Organization and the U.K. Meteorological Office.
'Higher global mean temperatures may sound abstract, but it translates in real life to a higher chance of extreme weather: stronger hurricanes, stronger precipitation, droughts,' said Cornell University climate scientist Natalie Mahowald, who wasn't part of the calculations but said they made sense. 'So higher global mean temperatures translates to more lives lost.'
With every tenth of a degree the world warms from human-caused climate change 'we will experience higher frequency and more extreme events (particularly heat waves but also droughts, floods, fires and human-reinforced hurricanes/typhoons),' emailed Johan Rockstrom, director of the Potsdam Institute for Climate Impact Research in Germany. He was not part of the research.
And for the first time there's a chance — albeit slight — that before the end of the decade, the world's annual temperature will shoot past the Paris climate accord goal of limiting warming to 1.5 degrees Celsius (2.7 degrees Fahrenheit) and hit a more alarming 2 degrees Celsius (3.6 degrees Fahrenheit) of heating since the mid-1800s, the two agencies said.
There's an 86% chance that one of the next five years will pass 1.5 degrees and a 70% chance that the five years as a whole will average more than that global milestone, they figured.
The projections come from more than 200 forecasts using computer simulations run by 10 global centers of scientists.
Ten years ago, the same teams figured there was a similar remote chance — about 1% — that one of the upcoming years would exceed that critical 1.5 degree threshold and then it happened last year. This year, a 2-degree Celsius above pre-industrial year enters the equation in a similar manner, something UK Met Office longer term predictions chief Adam Scaife and science scientist Leon Hermanson called 'shocking.'
'It's not something anyone wants to see, but that's what the science is telling us,' Hermanson said. Two degrees of warming is the secondary threshold, the one considered less likely to break, set by the 2015 Paris agreement.
Technically, even though 2024 was 1.5 degrees Celsius warmer than pre-industrial times, the Paris climate agreement's threshold is for a 20-year time period, so it has not been exceeded. Factoring in the past 10 years and forecasting the next 10 years, the world is now probably about 1.4 degrees Celsius (2.5 degrees Fahrenheit) hotter since the mid 1800s, World Meteorological Organization climate services director Chris Hewitt estimated.
'With the next five years forecast to be more than 1.5C warmer than preindustrial levels on average, this will put more people than ever at risk of severe heat waves, bringing more deaths and severe health impacts unless people can be better protected from the effects of heat. Also we can expect more severe wildfires as the hotter atmosphere dries out the landscape,' said Richard Betts, head of climate impacts research at the UK Met Office and a professor at the University of Exeter.
Ice in the Arctic — which will continue to warm 3.5 times faster than the rest of the world — will melt and seas will rise faster, Hewitt said.
What tends to happen is that global temperatures rise like riding on an escalator, with temporary and natural El Nino weather cycles acting like jumps up or down on that escalator, scientists said. But lately, after each jump from an El Nino, which adds warming to the globe, the planet doesn't go back down much, if at all.
'Record temperatures immediately become the new normal,' said Stanford University climate scientist Rob Jackson.
Seth Borenstein, The Associated Press

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Shooting leaves 1 dead, 11 hurt on a North Carolina street during a house party
Shooting leaves 1 dead, 11 hurt on a North Carolina street during a house party

CTV News

time8 hours ago

  • CTV News

Shooting leaves 1 dead, 11 hurt on a North Carolina street during a house party

In this image taken from WSOC video, various police and officials gather outside a community after a mass shooting, Sunday, June 1, 2025, in Hickory, a city in Catawba County, N.C. (WSOC via AP) HICKORY, N.C. — Gunfire erupted around a house party in western North Carolina early Sunday and one person was killed and 11 others were hurt, some with gunshot wounds and others with injuries from fleeing the shooting in a usually quiet residential neighborhood, sheriff's deputies said. Authorities said at least 80 shots were fired in the shooting that began at about 12:45 a.m. People reported running, ducking for cover and scrambling to their cars for safety. Hours later Sunday, law enforcement had made no arrests and was seeking tips from the public in the case. A statement from the Catawba County Sheriff's Office said a 58-year-old man, Shawn Patrick Hood, of Lenoir, was killed, the oldest of the victims who ranged in age from as young as 16. It said seven of the injured remained hospitalized late Sunday, though updates on their conditions were not immediately released. One of the victims was previously reported in critical condition. Authorities believe there was more than one shooter, a sheriff's spokesperson said. The agency said it was asking for people who attended the party to contact the office. Sheriff's office Maj. Aaron Turk aid at a news conference that the shooting occurred in a normally quiet neighbhoord in southwest Catawba County about 7 miles (11 kilometers) south of the city of Hickory. He said that about two hours before the shooting, someone in another home complained about noise from the party. He added that deputies responded but that investigators don't believe the noise complaint was the motivation for the shooting. Turk said the crime scene spanned several properties along a neighborhood road, covering about two acres (0.8 hectares), and included outdoor and indoor areas. The North Carolina State Bureau of Investigation and the Hickory Police Department are investigating the shooting. The FBI is also assisting in the case with a specialized evidence response team, officials said.

1 dead, 11 others injured in North Carolina overnight shooting
1 dead, 11 others injured in North Carolina overnight shooting

CTV News

time13 hours ago

  • CTV News

1 dead, 11 others injured in North Carolina overnight shooting

In this image taken from WSOC video, various police and officials gather outside a community after a mass shooting, Sunday, June 1, 2025, in Hickory, a city in Catawba County, N.C. (WSOC via AP) HICKORY, N.C. — One person is dead and at least 11 others were injured in a mass shooting during a party at a western North Carolina residence, according to the Catawba County Sheriff's Office. The shooting took place at about 12:45 a.m. Sunday in Hickory, a city in Catawba County. One victim is in critical condition and ten others are in serious condition at the hospital, according to the Sheriff's Office. The North Carolina State Bureau of Investigation and the Hickory Police Department are investigating. The Federal Bureau of Investigation is also assisting. No arrests have been made and the number of shots fired is not yet known. The Sheriff's Department has not released the victims' names or ages, but Major Aaron Turk said at a press conference the street is usually quiet. The Associated Press

Eli Lilly vs. Novo Nordisk: Which Stock Is the Winner of the Weight-Loss Drug Boom?
Eli Lilly vs. Novo Nordisk: Which Stock Is the Winner of the Weight-Loss Drug Boom?

Globe and Mail

time14 hours ago

  • Globe and Mail

Eli Lilly vs. Novo Nordisk: Which Stock Is the Winner of the Weight-Loss Drug Boom?

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 to an estimated $381.5 billion by 2033. Two pharmaceutical giants, Eli Lilly (LLY) and Novo Nordisk (NVO), dominate this market. Both companies have created GLP-1 receptor agonists that have transformed obesity treatment: Eli Lilly's Mounjaro (tirzepatide) and Zepbound, and Novo Nordisk's Ozempic and Wegovy (semaglutide). Let's see which company is ahead of the game and has the best investment case right now. The Case for Eli Lilly Stock Valued at $684 billion, Eli Lilly has been a standout performer in the global pharmaceutical industry. Aside from its obesity treatments, it is well-known for developing groundbreaking treatments for autoimmune diseases, cancer, diabetes, Alzheimer's, and other conditions. LLY stock has fallen 6.4% year-to-date, compared to the S&P 500 Index's ($SPX) gain of 0.1%. Recently, Eli Lilly announced that Zepbound has demonstrated superior efficacy in weight loss compared to Novo Nordisk's Wegovy. The SURMOUNT-5 trial found that participants on Zepbound lost more body weight and waist circumference over 18 months than those on Wegovy. This superior efficacy is due to tirzepatide's dual action as a GLP-1 and GIP agonist, which boosts weight-loss effects. Financially, Eli Lilly reported a 45% increase in revenue in the first quarter of 2025, reaching $12.73 billion, thanks to strong sales from Mounjaro and Zepbound. Adjusted earnings increased 29% to $3.34 per share during the quarter. Mounjaro, in particular, saw a 113% year-over-year sales increase to $3.8 billion worldwide. Zepbound's sales increased threefold from the same quarter last year. Aside from the success of its weight-loss drugs, the company's non-incretin portfolio includes successful oncology, neuroscience, and immunology drugs, which are driving growth. The company anticipates 2025 revenue to be in the range of $58 billion to $61 billion, representing year-over-year growth of 28% to 35%. Eli Lilly has taken proactive measures to capitalize on the weight-loss drug boom. The company has handled supply chain issues more effectively than Novo Nordisk, resulting in improved product availability. Last year, the company launched Mounjaro in all major European markets and provided early stage access in China. In order to increase accessibility, the company has formed partnerships with telehealth providers and launched direct-to-consumer initiatives. Furthermore, Lilly's investment in orforglipron, an oral GLP-1 receptor agonist, has yielded encouraging results in Phase 3 studies. Patients lost significant weight, and the convenience of a pill form could transform obesity treatment, making it more accessible and appealing to a larger patient base. On Wall Street, Eli Lilly has earned an overall ' Strong Buy ' rating. Of the 25 analysts who cover the stock, 20 rate it a 'Strong Buy,' two a 'Moderate Buy,' and three recommend a 'Hold.' The average analyst price target of $991.46 suggests a 34.7% increase from current levels. Furthermore, the Street-high estimate of $1,190 implies that the stock could rally by up to 62% over the next year. The Case for Novo Nordisk Stock Valued at $311.7 billion, Novo Nordisk is a Denmark-based pharmaceutical company specializing primarily in diabetes care, obesity treatment, and other chronic disease therapies. Novo Nordisk's Ozempic and Wegovy have been instrumental in the company's growth. However, Eli Lilly's weight loss drugs have demonstrated superior efficacy, challenging Novo Nordisk's market dominance. Novo's stock has fallen nearly 20% year to date, compared to the overall market. In the first quarter of 2025, Novo Nordisk reported earnings per share of 6.53 DKK, in line with analyst expectations. Sales rose 18% year on year to 78.08 billion DKK, led by a 15% rise in Ozempic sales and an 83% increase in Wegovy sales. Despite these gains, the company faces significant challenges due to increased competition and shifting market dynamics. As a result, Novo Nordisk lowered its full-year guidance, projecting 2025 sales growth of 13% to 21%, significantly lower than Lilly's projections. Analysts who cover the stock expect Novo's revenue to grow by 25.5%, followed by earnings growth of 26%. While Eli Lilly's drugs have demonstrated superior efficacy, according to Leerink Partners analyst David Risinger, most people are unaware that Zepbound outperforms Wegovy. As a result, Novo continues to hold 65% of the market, while Lilly holds 34%. However, this may soon change. On Wall Street, Novo Nordisk stock has earned an overall ' Moderate Buy ' rating. Of the 18 analysts who cover the stock, eight rate it a 'Strong Buy,' seven say it is a 'Hold,' one says it is a 'Moderate Sell,' and two suggest a 'Strong Sell.' The average analyst price target of $101.93 suggests a 44% increase from current levels. Furthermore, the Street-high estimate of $160 implies that the stock could rally by up to 128% over the next year. The Verdict: Eli Lilly Takes the Lead Both Eli Lilly and Novo Nordisk continue to strengthen their incretin portfolios. However, based on clinical efficacy, market performance, strategic initiatives, and leadership stability, Eli Lilly currently has a competitive advantage over Novo Nordisk in the weight-loss drug market. Overall, Eli Lilly stock represents a better long-term investment.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store